A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal crystal buildup, this therapy reflects ongoing efforts to improve both care and quality of life for those affected by cystinosis. Leadiant Biosciences has provided Cystaran in the U.S. for years and will now provide the same formulation to Canadians under the name Cysklar.
Read the full announcement here.